JP2022547952A5 - - Google Patents
Info
- Publication number
- JP2022547952A5 JP2022547952A5 JP2022515701A JP2022515701A JP2022547952A5 JP 2022547952 A5 JP2022547952 A5 JP 2022547952A5 JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022547952 A5 JP2022547952 A5 JP 2022547952A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- alkyl
- pharmaceutically acceptable
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900869P | 2019-09-16 | 2019-09-16 | |
| US201962900865P | 2019-09-16 | 2019-09-16 | |
| US201962900863P | 2019-09-16 | 2019-09-16 | |
| US201962900860P | 2019-09-16 | 2019-09-16 | |
| US62/900,863 | 2019-09-16 | ||
| US62/900,860 | 2019-09-16 | ||
| US62/900,865 | 2019-09-16 | ||
| US62/900,869 | 2019-09-16 | ||
| PCT/US2020/050768 WO2021055295A1 (en) | 2019-09-16 | 2020-09-14 | Brd9 bifunctional degraders and their methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547952A JP2022547952A (ja) | 2022-11-16 |
| JP2022547952A5 true JP2022547952A5 (cg-RX-API-DMAC7.html) | 2023-09-25 |
Family
ID=72915891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515701A Pending JP2022547952A (ja) | 2019-09-16 | 2020-09-14 | Ｂｒｄ９二機能性分解誘導薬及びその使用方法 |
Country Status (21)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746135A4 (en) | 2018-01-30 | 2022-03-09 | Foghorn Therapeutics Inc. | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE |
| CN111936498B (zh) | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| US20230066136A1 (en) | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| CR20220160A (es) | 2019-09-16 | 2022-06-16 | Takeda Pharmaceuticals Co | Derivados de piridazin-3(2h)-ona fusionados con azol |
| EP4096651A4 (en) * | 2020-01-29 | 2024-01-24 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商Ｃ４醫藥公司 | 用於標靶降解brd9之化合物 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| WO2023039208A1 (en) * | 2021-09-09 | 2023-03-16 | C4 Therapeutics, Inc. | Selected compounds for targeted degradation of brd9 |
| WO2023109892A1 (zh) * | 2021-12-15 | 2023-06-22 | 海思科医药集团股份有限公司 | 一种抑制或降解brd9的化合物及其组合物和药学上的应用 |
| WO2023200800A1 (en) * | 2022-04-11 | 2023-10-19 | Foghorn Therapeutics Inc. | Methods of treating androgen receptor-independent prostate cancer |
| WO2024163609A1 (en) * | 2023-02-01 | 2024-08-08 | Foghorn Therapeutics Inc. | Compositions for treating cancer |
| KR20260029501A (ko) | 2023-05-24 | 2026-03-04 | 베액티카 테라퓨틱스 아베 | Tead에 대한 결합제로서의 방향족 아미드 및 이의 접합체 |
| CN121816348A (zh) | 2023-08-11 | 2026-04-07 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
| CN117229202B (zh) * | 2023-11-15 | 2024-01-26 | 苏州美诺医药科技有限公司 | 一种brd9靶向降解化合物的中间体的制备方法 |
| WO2025256550A1 (zh) * | 2024-06-12 | 2025-12-18 | 杭州中美华东制药有限公司 | 靶向降解剂配体及连接基的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US11319318B2 (en) * | 2015-03-05 | 2022-05-03 | Boehringer Ingelheim International Gmbh | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 |
| WO2017223452A1 (en) * | 2016-06-23 | 2017-12-28 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
| WO2018064589A1 (en) * | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3710443A1 (en) * | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| JP2021506848A (ja) * | 2017-12-18 | 2021-02-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｅ３ユビキチンリガーゼ部分を持つｅｇｆｒを有する二官能性阻害剤 |
| WO2019140387A1 (en) * | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3774808A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives |
| CN111936498B (zh) * | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| WO2020051235A1 (en) * | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| EP3917517A4 (en) * | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| CN113874016A (zh) * | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
-
2020
- 2020-09-14 JP JP2022515701A patent/JP2022547952A/ja active Pending
- 2020-09-14 WO PCT/US2020/050768 patent/WO2021055295A1/en not_active Ceased
- 2020-09-14 PE PE2022000406A patent/PE20221417A1/es unknown
- 2020-09-14 AU AU2020349451A patent/AU2020349451B2/en not_active Ceased
- 2020-09-14 TW TW109131573A patent/TW202123942A/zh unknown
- 2020-09-14 CN CN202080061458.1A patent/CN114641473A/zh active Pending
- 2020-09-14 EP EP20793192.4A patent/EP4041724A1/en active Pending
- 2020-09-14 PY PY202002054376A patent/PY2054376A/es unknown
- 2020-09-14 CR CR20220105A patent/CR20220105A/es unknown
- 2020-09-14 PH PH1/2022/550611A patent/PH12022550611A1/en unknown
- 2020-09-14 CA CA3153529A patent/CA3153529A1/en active Pending
- 2020-09-14 BR BR112022003514A patent/BR112022003514A2/pt unknown
- 2020-09-14 MX MX2022003102A patent/MX2022003102A/es unknown
- 2020-09-14 KR KR1020227010572A patent/KR20220063192A/ko not_active Ceased
- 2020-09-14 US US17/020,114 patent/US20220315578A1/en active Pending
- 2020-09-14 UY UY0001038880A patent/UY38880A/es not_active Application Discontinuation
-
2022
- 2022-02-16 IL IL290677A patent/IL290677A/en unknown
- 2022-03-10 DO DO2022000053A patent/DOP2022000053A/es unknown
- 2022-03-11 CO CONC2022/0002842A patent/CO2022002842A2/es unknown
- 2022-03-11 EC ECSENADI202218571A patent/ECSP22018571A/es unknown
- 2022-03-15 JO JOP/2022/0069A patent/JOP20220069A1/ar unknown